VELCADEXA: A National, Multi-Center, Open-Label Study of Pretransplant Induction With Alternating VELCADE [bortezomib] and Dexamethasone (VEL/Dex) in Younger (less than 65 Yrs) Untreated Multiple Myeloma Patients
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms VELCADEXA
- 22 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Nov 2008 Planned end date changed from 1 Jan 2008 to 1 Jan 2008.
- 03 Nov 2006 New trial record.